Aradigm Corp. Company Profile (NASDAQ:ARDM)

About Aradigm Corp.

Aradigm Corp. logoAradigm Corporation is a pharmaceutical company. The Company is focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin, which is in Phase III clinical trials. The Company also invested on AERx pulmonary drug delivery platform and other technologies. The Company's partnered programs under development include Inhaled Ciprofloxacin. The Company is also developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine) program. Its lead development candidates are the Company's formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARDM
  • CUSIP:
Key Metrics:
  • Previous Close: $4.74
  • 50 Day Moving Average: $4.671
  • 200 Day Moving Average: $4.272
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: Infinity
  • P/E Growth: 0.000
  • Market Cap: $69.31M
  • Outstanding Shares: 14,781,000
  • Beta: 0.99
Additional Links:
Companies Related to Aradigm Corp.:

Analyst Ratings

Consensus Ratings for Aradigm Corp. (NASDAQ:ARDM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Aradigm Corp. (NASDAQ:ARDM)
No equities research coverage for this company has been tracked by


Earnings History for Aradigm Corp. (NASDAQ:ARDM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2016Q2($0.59)($0.59)ViewN/AView Earnings Details
5/10/2016Q1($0.59)($0.55)ViewN/AView Earnings Details
3/15/2016Q415($0.55)($0.63)ViewN/AView Earnings Details
11/11/2015Q3($0.19)($0.38)ViewN/AView Earnings Details
8/13/2015Q2($0.08)($0.08)$11.60 million$10.00 millionViewN/AView Earnings Details
5/11/2015Q1($0.06)($0.08)ViewN/AView Earnings Details
3/17/2015Q414($0.07)($0.06)$6.70 million$8.10 millionViewN/AView Earnings Details
11/7/2014Q314($0.10)($0.06)$4.80 million$6.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)($0.09)$4.25 million$12.20 millionViewN/AView Earnings Details
10/28/2013Q3 13($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aradigm Corp. (NASDAQ:ARDM)
Current Year EPS Consensus Estimate: $-1.92 EPS


Dividend History for Aradigm Corp. (NASDAQ:ARDM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Aradigm Corp. (NASDAQ:ARDM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/21/2016Juergen Kurt FroehlichInsiderSell333$4.45$1,481.85View SEC Filing  
12/13/2013Virgil ThompsonDirectorSell3,340$0.17$567.80View SEC Filing  
8/27/2013First Eagle Investment ManagemMajor ShareholderBuy40,322,580$0.12$4,838,709.60View SEC Filing  
12/11/2012First Eagle Investment ManagemMajor ShareholderBuy41,666,667$0.12$5,000,000.04View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Aradigm Corp. (NASDAQ:ARDM)
DateHeadline logoAradigm Corp. :ARDM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:ARDM) - August 12 at 12:07 PM logoAradigm reports 2Q loss (NASDAQ:ARDM) - August 10 at 9:40 AM logoAradigm Announces Second Quarter 2016 Financial Results (NASDAQ:ARDM) - August 10 at 9:40 AM logoARADIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:ARDM) - June 10 at 5:02 PM logoAradigm Corp. :ARDM-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:ARDM) - May 17 at 12:15 PM logoTwo Presentations on Aradigm's Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference (NASDAQ:ARDM) - May 11 at 7:22 AM logoTwo Presentations on Aradigm’s Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference (NASDAQ:ARDM) - May 11 at 7:00 AM logoAradigm reports 1Q loss (NASDAQ:ARDM) - May 10 at 9:03 AM logoAradigm Announces First Quarter 2016 Financial Results (NASDAQ:ARDM) - May 10 at 7:08 AM logoActivist Starboard Value Gets Seats on Marvell Technology Group Ltd. (MRVL)’s Board; Two Other Hedge Funds Disclose Latest Moves (NASDAQ:ARDM) - April 29 at 9:42 AM logoARADIGM CORP Files SEC form 8-K/A, Financial Statements and Exhibits (NASDAQ:ARDM) - April 28 at 4:08 PM logoARADIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio (NASDAQ:ARDM) - April 27 at 4:30 PM logoAradigm Corporation Announces First Closing of Private Placement Offering of $23 Million Senior Convertible Notes Due 2021 (NASDAQ:ARDM) - April 26 at 7:26 AM logoARADIGM CORP Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:ARDM) - April 25 at 12:08 PM logoSlew of results disappointments hamstring S&P (NASDAQ:ARDM) - April 23 at 6:45 AM logoAradigm Corporation Prices Private Placement of Senior Notes (NASDAQ:ARDM) - April 22 at 8:36 AM logoARADIGM CORP Files SEC form 10-K, Annual Report (NASDAQ:ARDM) - March 30 at 2:33 PM logo7:00 am Aradigm announces that the EMA has approved its request to review Pulmaquin under the Centralised Authorisation Procedure drug review process (NASDAQ:ARDM) - March 17 at 7:00 AM logoAradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency (NASDAQ:ARDM) - March 17 at 7:00 AM logoAradigm reports 4Q loss (NASDAQ:ARDM) - March 15 at 7:13 AM logoAradigm Announces Fourth Quarter 2015 and Full Year Financial Results (NASDAQ:ARDM) - March 15 at 7:00 AM logoAradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016 on February 8 (NASDAQ:ARDM) - February 2 at 7:00 AM logoAradigm to Host Corporate Update Conference Call on January 6 (NASDAQ:ARDM) - January 5 at 7:28 AM logoAradigm Corp.: Sudden move in price, will it continue? (NASDAQ:ARDM) - December 23 at 5:16 PM logoAradigm Corp. Earnings Analysis: Q3, 2015 By the Numbers (NASDAQ:ARDM) - December 21 at 12:11 PM logoARADIGM CORP Financials (NASDAQ:ARDM) - December 8 at 1:17 PM logoHow it All Plays Out - Research on Aradigm, Ideal Power, CareDx, and Colony Bankcorp (NASDAQ:ARDM) - December 3 at 8:40 AM logoARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:ARDM) - November 12 at 3:20 PM logoARADIGM CORP Files SEC form 10-Q, Quarterly Report (NASDAQ:ARDM) - November 12 at 6:12 AM logoAradigm Announces Third Quarter 2015 Financial Results (NASDAQ:ARDM) - November 11 at 7:16 AM logoAradigm reports 3Q loss (NASDAQ:ARDM) - November 11 at 7:06 AM logoAradigm Corp. – Value Analysis (NASDAQ:ARDM) : October 30, 2015 (NASDAQ:ARDM) - October 30 at 3:19 PM logoAradigm Corporation Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3) (NASDAQ:ARDM) - October 13 at 7:00 AM logoAradigm to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29 (NASDAQ:ARDM) - September 23 at 7:25 AM


Aradigm Corp. (NASDAQ:ARDM) Chart for Saturday, August, 27, 2016

Last Updated on 8/27/2016 by Staff